November 20, 2023
Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic HypoparathyroidismNEWS RELEASES
November 15, 2023
Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDANovember 7, 2023
Ascendis Pharma Reports Third Quarter 2023 Financial ResultsPreclinical
Phase 1
Phase 2
Phase 3
TransCon hGH
Pediatric growth hormone deficiency2
test
Phase 1
test
Adult growth hormone deficiency
Phase 1
TransCon PTH
Adult hypoparathyroidism
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
sss
ss
Phase 1
ss
sdsd
sss
Phase 2
sss
sds
ss
Phase 3
ss